ENX-105
ENX-105 is an investigational new drug being developed by Engrail Therapeutics for the treatment of post-traumatic stress disorder (PTSD).
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ENX-105 is an investigational new drug being developed by Engrail Therapeutics for the treatment of post-traumatic stress disorder (PTSD). It is currently in the preclinical stage, trailing behind a closely related Engrail compound, ENX-104, which is focused on depression and anhedonia.
The drug is described as a dopamine D 2 and D 3 receptor antagonist and serotonin 5-HT 1A and 5-HT 2A receptor agonist. Its antagonistic potencies ( ) are 0.08 nM at the dopamine D 2L receptor, 0.8 nM at the dopamine D 2S receptor, and 3.8 nM at the dopamine D 3 receptor, whereas its activational potencies ( ) are 5 nM at the serotonin 5-HT 2A receptor and 16 nM at the serotonin 5-HT 1A receptor.
ENX-105 does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence is putatively non-hallucinogenic. The drug has shown anxiolytic-, antipsychotic-, anti-anhedonic-, and pro-cognitive-like effects in rodents. It has also been found to increase dopamine levels in the nucleus accumbens in rodents.
As with ENX-104, ENX-105 is a deuterated enantiomer of nemonapride.
See also
List of investigational hallucinogens and entactogens Non-hallucinogenic 5-HT 2A receptor agonist ENX-104 and ENX-205
Text derived from https://en.wikipedia.org/w/index.php?oldid=1331787348 under CC BY-SA 4.0; modifications have been made.